https://hdl.handle.net/20.500.14178/903 2026-08-19T11:24:24Z 2026-08-19T11:24:24Z Koudelková, Marcela Hejcmanová, Katerina Babjuk, Marek Zachoval, Roman Ferda, Jiří Bratt, Ola Chloupková, Renata Ngo, Ondřej Hejduk, Karel Válek, Vlastimil Dušek, Ladislav Májek, Ondřej https://hdl.handle.net/20.500.14178/3890 2026-08-13T01:00:19Z 2026-01-01T00:00:00Z

Implementation and First Results of the Czech Nationwide Prostate Cancer Screening Pilot Program Koudelková, Marcela; Hejcmanová, Katerina; Babjuk, Marek; Zachoval, Roman; Ferda, Jiří; Bratt, Ola; Chloupková, Renata; Ngo, Ondřej; Hejduk, Karel; Válek, Vlastimil; Dušek, Ladislav; Májek, Ondřej Background: In 2022, the European Union recommended piloting organized prostate cancer screening. Subsequently, the Czech Republic launched a nationwide pilot program fully reimbursed by public health insurance in January 2024 to reduce the high incidence of late-stage prostate cancer and the widespread unorganized prostate-specific antigen (PSA) testing. Objective: To describe the strategy, methodology, and first results of the Czech nationwide prostate cancer screening pilot program. Design, setting, and participants: We analyzed data from the first 12 mo of the program targeting men aged 50-69 yr without a previous diagnosis of prostate cancer. General practitioners and urologists offer men an initial PSA test. Those with PSA >= 3.0 lg/l are referred to certified urologists. Based on urology assessment, selected for magnetic resonance imaging (MRI) and, if indicated, targeted biopsy. Outcome measurements and statistical analysis: Reported key indicators are PSA testing coverage and overall use of prebiopsy MRI. Results and limitations: Screening was offered to 150 498 men; PSA results were available for 146 109 (97.1%) men, 8.8% of whom had PSA >= 3.0 lg/l. Within 6 mo, 67.2% of the men with PSA >= 3.0 lg/l underwent urological evaluation. From 2023 to 2024, the 2-yr PSA testing rate rose from 47.4% to 53.3%, and pre-biopsy MRI use increased from 28.0% to 38.3% (10.3 percentage-point difference, 95% confidence interval 8.3-12.2). Data on diagnostic outcomes are not yet analyzed.

2026-01-01T00:00:00Z Gayibov, Emin Sychra, Tomáš Spálenková, Alžběta Šeborová, Karolína Koucká, Kamila Tesařová, Tereza Kočí, Kamila Vícha, Matěj Szabó, Arpád Václavíková, Radka Šubrt, Zdeněk Souček, Pavel Oliverius, Martin https://hdl.handle.net/20.500.14178/3699 2026-03-14T02:00:25Z 2025-01-01T00:00:00Z

Determinants of Implantation Success in Pancreatic Cancer Patient-Derived Xenografts: Role of Matrigel Application, Histological Subtype, and Time Management Gayibov, Emin; Sychra, Tomáš; Spálenková, Alžběta; Šeborová, Karolína; Koucká, Kamila; Tesařová, Tereza; Kočí, Kamila; Vícha, Matěj; Szabó, Arpád; Václavíková, Radka; Šubrt, Zdeněk; Souček, Pavel; Oliverius, Martin Pancreatic cancer (PC) is a growing global health concern, highlighting the need for improved preclinical models. Patient-derived xenografts (PDXs) closely replicate tumor biology and serve as a vital link between preclinical and clinical research. This study investigated the key factors influencing the success of PDX implantation in PC. We compared Matrigel-assisted implantation versus Matrigel-free implantation. We also evaluated the impact of histological subtype on implantation success, analyzing pancreatic ductal adenocarcinoma (PDAC), adenosquamous carcinoma (ASPC), and acinar cell carcinoma (ACC). Additionally, we assessed whether the tumor specimen culture-to-implantation period affected both the take rate and tumor growth rate. A significance threshold of p < 0.05 was applied (95% confidence interval), and multivariable regression analysis was conducted to identify independent predictors of implantation success. In both NOD/SCID and NU/NU (nude) strains, Matrigel-assisted PDAC implantations achieved significantly higher take rates (75% vs. 90%) compared to direct implantations (25% vs. 0%) in the second generation (p = 0.02). The ASPC subtype was a significant predictor of success in the NOD/SCID strain (p = 0.04). The culture-to-implantation period did not affect take rates. The nude strain significantly prolonged ACC engraftment (p = 0.02). In direct ACC implantations, earlier generations (F1-F5) required shorter engraftment growth duration (p < 0.0001). For ASPC, later generations demonstrated longer growth duration (p < 0.04). These findings emphasize critical variables in optimizing PC PDX protocols, particularly Matrigel use, mouse strain selection, and consideration of histological and generation-specific effects. Such refinements can optimize PDX efficiency and translational relevance.

2025-01-01T00:00:00Z Rosová, Blanka Filipová, Alžběta Hadzi Nikolov, Dimitar Drösslerová, Marie Matěj, Radoslav Rozsypalová, Aneta Richter, Igor Melichar, Bohuslav Mahel, Rostislav Štěpánová, Radka Lohynská, Radka Dvořák, Josef https://hdl.handle.net/20.500.14178/3479 2026-01-30T02:00:22Z 2024-01-01T00:00:00Z

Negative prognostic significance of primary cilia and cytoplasmic β-catenin expression in non-small cell lung cancer Rosová, Blanka; Filipová, Alžběta; Hadzi Nikolov, Dimitar; Drösslerová, Marie; Matěj, Radoslav; Rozsypalová, Aneta; Richter, Igor; Melichar, Bohuslav; Mahel, Rostislav; Štěpánová, Radka; Lohynská, Radka; Dvořák, Josef The objective of this study was to investigate the prognostic significance of the frequency of primary cilia (PC) and β-catenin expression in 218 patients (pts) with non-small cell lung cancer (NSCLC), including 125 pts with adenocarcinoma and 93 pts with squamous cell carcinoma. In the whole group of 218 pts with NSCLC, overall survival (OS) was significantly inferior among pts with present PC than without PC (p=0.024) and with higher cytoplasmic β-catenin expression (25-75%) than with lower cytoplasmic β-catenin expression (<25%) (p=0.008). In the univariate Cox proportional hazard model, the hazard ratio was 1.653 in pts with present PC (p=0.026) and 1.851 in pts with higher cytoplasmic β-catenin (25-75%) (p=0.009). Multivariate testing of the whole group of 218 pts with NSCLC showed that the presence of PC was associated with a worse prognosis (p=0.018). In the subgroup of 125 pts with adenocarcinoma, OS was significantly improved in pts with higher membranous β-catenin expression (>=50%) than in pts with lower expression (<50%) (p=0.0300) and OS was significantly inferior in pts with higher cytoplasmic β-catenin expression (25-75%) than in pts with lower expression (<25%) (p=0.0004). Multivariate testing of the subgroup of pts with adenocarcinoma showed that cytoplasmic β-catenin (p<0.001) and pleural invasion (p=0.017) were associated with worse prognosis. The present results indicate a negative prognostic significance of PC and cytoplasmic β-catenin expression in NSCLC and a negative prognostic significance of cytoplasmic β-catenin expression in adenocarcinoma.

2024-01-01T00:00:00Z Heřman, Dalibor Peichl, Petr Hozman, Marek Janek, Bronislav Kníže, Tomáš Víchová, Teodora Línková, Hana Veselá, Jana Karch, Jakub Valošková, Naďa Borisincová, Eva Osmančík, Pavel https://hdl.handle.net/20.500.14178/3403 2026-01-03T02:00:16Z 2025-01-01T00:00:00Z

Acute and Short-Term Hemodynamic and Echocardiography Changes During and After Left Atrial Appendage Closure Heřman, Dalibor; Peichl, Petr; Hozman, Marek; Janek, Bronislav; Kníže, Tomáš; Víchová, Teodora; Línková, Hana; Veselá, Jana; Karch, Jakub; Valošková, Naďa; Borisincová, Eva; Osmančík, Pavel Background: The left atrial appendage (LAA) plays an important role as a reservoir and has endocrine functions. This study aimed to assess the acute hemodynamic effects associated with LAA closure (LAAC) and ensuing structural changes 3 months after closure. Methods: Two centers enrolled patients for LAAC from January 2022 to July 2024. Invasive hemodynamic measurements of left atrial pressure (LAP) were taken after the transseptal puncture and postdevice deployment (both before and after isometric exercise). The heart failure (HF) biomarkers (NT-proBNP, NT-proANP, and GDF-15) were assessed before and 3 months after LAAC. The echocardiographic parameters were assessed before and 6 months after LAAC. Results: Sixty-two patients participated (age 75.7 +- 8.2 years, 45 (72.6%) males, CHA<inf>2</inf>DS<inf>2</inf>VASc 4.1 +- 1.3). Both rest and postexercise LAP values increased after device implantation (rest: 14.9 +- 7.1 before vs. 17.6 +- 7.9 mm Hg after, p < 0.001; postexercise: 18.7 +- 8.6 before vs. 21.8 +- 9.5 mm Hg after, p < 0.001). The administration of larger volumes of fluid during the procedure was significantly correlated with a higher increase in resting LAP following device implantation. On the other hand, exercise-induced changes in postprocedural LAP (i.e., the difference between postexercise vs. rest) were negatively associated with the amount of fluid administered during the procedure. Three months postprocedure, we observed no changes in HF biomarkers. Six months postprocedure, we observed no changes in LA and LV echocardiographic parameters. Conclusions: LAAC caused an acute increase in both rest and exercise LAP. The amount of procedural fluid is one of the most important parameters associated with LAP changes.

2025-01-01T00:00:00Z